Abstract:Background Methylenetetrahydrofolate reductase (MTHFR) is a key enzyme in the metabolism of folate. The non-synonymous single nucleotide polymorphism (nsSNP), C677T (Ala>Val, rs1801133), has been verified to impair enzyme activity. The association with cancer susceptibility, including hepatocellular carcinoma (HCC), has also been widely studied. The results, however, were inconsistent. To shed light on the influence of MTHFR C677T polymorphism on HCC, a meta-analysis was conducted. Methods The meta-analysis of C677T consisted of 10 studies (1814 cases/2862 controls). The association was measured by using random-effect (RE) or fixed-effect (FE) odds ratio (OR) combined with 95% confidence intervals (CIs) according to the studies' heterogeneity. Results Using genetic model analysis, C677T polymorphism was found to increase the risk of HCC in a complete overdominant model, which indicates that heterozygotes CT are at a lesser risk of HCC than either homozygotes CC or TT. Meta-analyses of the 10 studies showed that the TT genotype increased the risk of HCC as compared to the CT genotype: FE OR was 1.20 (95%CI: 1.00-1.45, p for heterogeneity = 0.21). When subgroup analysis was done between the HCC cases and the chronic liver disease (CLD) patients of four studies, meta-analysis showed that individuals with the TT genotype had increased HCC risk compared with those with the CT genotype: FE OR (TT vs. CT) reached 1.81 (1.22-2.71, p for heterogeneity = 0.25). Meanwhile, the C677T polymorphism also increased HCC risk in a recessive model when cases were compared to CLD patients of four studies: RE OR reached 1.85 (95%CI: 1.00-3.42, p for heterogeneity = 0.06). Overall, there was some extent heterogeneity when analyses were performed in various models. There was no publication bias. Conclusion MTHFR C677T polymorphism increased the risk of HCC in an overdominant model, and might be a risk factor for HCC occurrence, especially in CLD patients. The association warranted further studies.

Associations Between Methylenetetrahydrofolate Reductase (MTHFR) Polymorphisms and Non-Alcoholic Fatty Liver Disease (NAFLD) Risk: A Meta-Analysis.

Association Between the MTHFR A1298C Polymorphism and Risk of Cancer: Evidence from 265 Case–control Studies

Mthfr C677t Polymorphism And Risk Of Congenital Heart Defects: Evidence From 29 Case-Control And Tdt Studies

Diets, polymorphisms of methylenetetrahydrofolate reductase, and the susceptibility of colon cancer and rectal cancer.

FOLIC ACID,METHIONINE,AND POLYMORPHISMS OF METHYLENETETRAHYDROFOLATE REDUCTASES AND SUSCEPTIBILITY OF COLORECTAL CANCER

Meta-analysis on the Relationship Between MTHFR Gene Polymorphisms and Colorectal Cancer

Methylenetetrahydrofolate Reductase Gene Rs1801131 and Rs1801133 Polymorphisms Were Associated with Susceptibility to Coronary Artery Disease and Nonalcoholic Fatty Liver Disease

Methylenetetrahydrofolate Reductase Polymorphisms and Breast Cancer Risk: a Meta-Analysis from 41 Studies with 16,480 Cases and 22,388 Controls

Association Between the Methylenetetrahydrofolate Reductase C677T Polymorphism and Hepatocellular Carcinoma Risk: a Meta-Analysis

MTHFR C677T and A1298C polymorphisms and risk of lung cancer: a comprehensive evaluation.

Different roles of MTHFR C677T and A1298C polymorphisms in colorectal adenoma and colorectal cancer: a meta-analysis

Meta-analysis of the Association Between MTHFR A1298C Polymorphism and Susceptibility to Hepatocellular Carcinoma

Associations between methylenetetrahydrofolate reductase polymorphisms and hepatocellular carcinoma risk in Chinese population

The MTHFR C677T/A1298C polymorphism is associated with increased risk of microangiopathy in type 2 diabetes mellitus: A systematic review and meta-analysis

The polymorphism of methylenetetrahydrofolate reductase C677T but not A1298C contributes to gastric cancer

The Methylenetetrahydrofolate Reductase Genotype 677CT and Non-Alcoholic Fatty Liver Disease Have a Synergistic Effect on the Increasing Homocysteine Levels in Subjects from Chongqing, China.

Association of MTHFR C677T and A1298C polymorphisms with non-Hodgkin lymphoma susceptibility: Evidence from a meta-analysis

Methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C polymorphisms and the risk of primary Hepatocellular Carcinoma (HCC) in a Chinese population

The Polymorphisms in Methylenetetrahydrofolate Reductase, Methionine Synthase, Methionine Synthase Reductase, and the Risk of Colorectal Cancer

The Methylenetetrahydrofolate Reductase ( MTHFR ) C677T Polymorphism and Tumor Risk: Evidence from 134 Case–control Studies

Association Between Mthfr Polymorphisms and Congenital Heart Disease: A Meta-Analysis Based on 9,329 Cases and 15,076 Controls